Condition context
GLP-1 and fatty liver: metabolic context and doctor review
Fatty liver can have different causes and degrees of risk. It should be assessed rather than assumed from symptoms or body weight alone.
Why metabolic factors matter
Metabolic dysfunction-associated steatotic liver disease is often considered alongside weight, blood glucose, lipids and cardiovascular risk.
The presence of fatty liver does not by itself select a medicine or prove that a GLP-1 pathway is appropriate.
Assessment comes before treatment
A clinician may consider liver tests, imaging, fibrosis risk, alcohol use, other medicines and alternative causes.
More advanced disease or unclear findings may require specialist evaluation.
A coordinated support role
ZentraHealth can help organise questions, nutrition habits and follow-up reminders around doctor-led care.
It does not diagnose liver disease, interpret individual results or change prescription treatment.
Frequently asked questions
Does fatty liver automatically mean GLP-1 is suitable?
No. Diagnosis, severity, other causes, medical history and available options all need clinical review.
Can an online page stage liver disease?
No. Staging may require clinical assessment, tests and sometimes specialist input.
Are labs included in the Companion Plan?
No. Laboratory charges and external clinical services are separate unless explicitly confirmed.
References and source material
These sources support the educational context on this page. Product labels and recommendations can change; local medical evaluation remains essential.
- Clinical Practice Guidelines on MASLD — EASL, EASD and EASO
- Wegovy (semaglutide) prescribing information — U.S. Food and Drug Administration
Continue with the route that fits your situation
Use the suitability guide if you are still researching, or activate structured support when you are ready. Payment never guarantees a prescription or medical suitability.